AddLife AB (publ)

OM:ALIF B Stock Report

Market Cap: SEK 16.7b

AddLife Valuation

Is ALIF B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALIF B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALIF B (SEK137.2) is trading below our estimate of fair value (SEK162.93)

Significantly Below Fair Value: ALIF B is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALIF B?

Key metric: As ALIF B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ALIF B. This is calculated by dividing ALIF B's market cap by their current earnings.
What is ALIF B's PE Ratio?
PE Ratio142.9x
EarningsSEK 117.00m
Market CapSEK 16.72b

Price to Earnings Ratio vs Peers

How does ALIF B's PE Ratio compare to its peers?

The above table shows the PE ratio for ALIF B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.9x
BIOT Biotage
49.5x19.5%SEK 12.7b
MCAP MedCap
39xn/aSEK 8.9b
GENO Genovis AB (publ.)
58.6x16.4%SEK 1.6b
MAGLE Magle Chemoswed Holding
36.5xn/aSEK 610.9m
ALIF B AddLife
142.9x52.0%SEK 16.7b

Price-To-Earnings vs Peers: ALIF B is expensive based on its Price-To-Earnings Ratio (142.9x) compared to the peer average (45.9x).

Price to Earnings Ratio vs Industry

How does ALIF B's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
ALIF B 142.9xIndustry Avg. 38.2xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ALIF B is expensive based on its Price-To-Earnings Ratio (142.9x) compared to the European Life Sciences industry average (38.6x).

Price to Earnings Ratio vs Fair Ratio

What is ALIF B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALIF B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio142.9x
Fair PE Ratio75.6x

Price-To-Earnings vs Fair Ratio: ALIF B is expensive based on its Price-To-Earnings Ratio (142.9x) compared to the estimated Fair Price-To-Earnings Ratio (75.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALIF B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 137.20
SEK 165.50
+20.6%
0.3%SEK 166.00SEK 165.00n/a2
Dec ’25SEK 133.10
SEK 165.50
+24.3%
0.3%SEK 166.00SEK 165.00n/a2
Nov ’25SEK 136.00
SEK 165.50
+21.7%
0.3%SEK 166.00SEK 165.00n/a2
Oct ’25SEK 159.50
SEK 168.00
+5.3%
1.8%SEK 171.00SEK 165.00n/a2
Sep ’25SEK 163.00
SEK 168.00
+3.1%
1.8%SEK 171.00SEK 165.00n/a2
Aug ’25SEK 156.00
SEK 168.00
+7.7%
1.8%SEK 171.00SEK 165.00n/a2
Jul ’25SEK 125.30
SEK 142.50
+13.7%
2.5%SEK 146.00SEK 139.00n/a2
Jun ’25SEK 114.40
SEK 137.00
+19.8%
1.5%SEK 139.00SEK 135.00n/a2
May ’25SEK 102.60
SEK 137.00
+33.5%
1.5%SEK 139.00SEK 135.00n/a2
Apr ’25SEK 112.00
SEK 136.50
+21.9%
4.8%SEK 143.00SEK 130.00n/a2
Mar ’25SEK 102.40
SEK 136.50
+33.3%
4.8%SEK 143.00SEK 130.00n/a2
Feb ’25SEK 111.80
SEK 132.00
+18.1%
1.5%SEK 134.00SEK 130.00n/a2
Jan ’25SEK 109.40
SEK 111.00
+1.5%
9.9%SEK 122.00SEK 100.00n/a2
Dec ’24SEK 97.30
SEK 111.00
+14.1%
9.9%SEK 122.00SEK 100.00SEK 133.102
Nov ’24SEK 73.35
SEK 118.00
+60.9%
15.3%SEK 136.00SEK 100.00SEK 136.002
Oct ’24SEK 64.75
SEK 135.50
+109.3%
0.4%SEK 136.00SEK 135.00SEK 159.502
Sep ’24SEK 75.50
SEK 135.50
+79.5%
0.4%SEK 136.00SEK 135.00SEK 163.002
Aug ’24SEK 85.10
SEK 135.50
+59.2%
0.4%SEK 136.00SEK 135.00SEK 156.002
Jul ’24SEK 121.70
SEK 152.50
+25.3%
1.6%SEK 155.00SEK 150.00SEK 125.302
May ’24SEK 121.20
SEK 137.50
+13.4%
1.8%SEK 140.00SEK 135.00SEK 102.602

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 04:20
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AddLife AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Karl NorénDanske Bank
Gustav BernebladNordea Markets